SREBF2 and neuroblastoma: As expected, BET blockade significantly suppressed the expression of SREBP-2 and of its targets LDLr and HMGCR also in the neuroblastoma cell line N1E-115 (Figure 5A,B) and in primary culture of human fibroblasts (Figure 5C,D).